Mannkind Corp (MNKD) Earnings Preview For Wednesday's Release
Mannkind (NASDAQ:MNKD) is anticipated to report earnings after the closing bell on February 22, 2012.
Who They Are:
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States, Europe, and Asia. The company was founded in 1991 and is headquartered in Valencia, California. Mannkind Corp trades an average of 3.4 million shares per day and has a marketcap of $299.45 Million.
52 Week High: $4.75
52 Week Low: $2.14
Book Value: $-2.14
Float Short: 37.73%
What To Expect:
The estimated mean earnings are $-0.32 per share .
Analyst estimates range between $-0.37 and $-0.23 per share.
Here is a look at the fiscal year revenue for Mannkind.
Recent Stock and Valuation Performance:
Looking at the price movement over the last month, the stock has fallen in price -19.15%, and moving in price -41.09% from one year ago.
When comparing to the S&P 500, the year to date difference is -15.74%.
The bottom line has rising earnings year-over-year of $-170.56 million for 2010 vs. $-220.10 million for 2009.The company's earnings before interest and taxes are rising with an EBIT year-over-year of $-152.50 million for 2010 vs. $-209.78 million for 2009. Rising revenue along with rising earnings is a very good sign and what we want to see with our companies. Be sure to check the margins in the earnings release to make sure the bottom line is keeping up with the top line.
The short interest is relatively high at 37.73%.
Paid2Trade uses information believed to be correct, but is not guaranteed and is not independently checked for accuracy You may wish to use this article as a starting point of your own research with your financial planner. Seeking Alpha, Edgar Online, Zacks and Yahoo Finance provides most of the data. paid2trade.com uses the confirmed symbols from earnings.com that believed to be of the most interest.